Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.9 USD | -0.99% | -7.59% | -8.71% |
May. 01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
Apr. 30 | Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours | MT |
Evolution of the average Target Price on Exelixis, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Exelixis, Inc.
RBC Capital Markets | |
Barclays | |
BTIG | |
Citigroup | |
Guggenheim | |
JMP Securities | |
Oppenheimer | |
SVB Securities LLC | |
Morgan Stanley | |
Wells Fargo Securities | |
Credit Suisse | |
EF Hutton | |
Truist Securities | |
Piper Sandler | |
BMO Capital | |
Jefferies & Co. | |
HC Wainwright | |
Needham & Co. | |
Goldman Sachs | |
Wolfe Research |
EPS Revisions
- Stock Market
- Equities
- EXEL Stock
- Consensus Exelixis, Inc.